Assessment of a point-of-care assay for cardiac biomarkers for patients suspected of acute myocardial infarction

Purpose:Hospitals and outpatient clinics are now relating point-of-care testing (POCT) devices that contract for the use of diagnostic analyses at the site of patient care delivery, so, facilitating earlier decision-making besides fast treatment. In our study, the aim was to assess the quantitative Nano-Ditech (Cranbury, NJ, USA), CK-MB, cTnI and myoglobin POC assays and to compare them with the Getein 1100 (Nanjing, China) CK-MB, cTnI and myoglobin POC assays Materials and Methods:Lithium heparin plasma samples (Terumo Europe N.V. Leuven, Belgium,) for Getein 1100 and Nano-Ditech cardiac marker determinations were randomly collected from among routine samples from 100 patients (53 male and 47 female) with chest pain complaint who admitted to Bilecik Golpazar？ Government Hospital between August-September 2017 and all analyses were performed using the Nano-Ditech analyzer and comparative analyses were performed by the Getein 1100) assays. Results:In our study, the correlation between the two devices was found to be r = 0.023 and p=0.017 for troponin, r = 0.130 and p=<0.001 for CK-MB and there is no correlation for myoglobin. Conclusion: According to evaluation of both devices’ analytical performances, it was found that the comparison of the all values of troponin, CK-MB and myoglobin, which are important for the diagnosis and exclusion of acute myocardial infarction(AMI), is discordant with the method comparison protocol proposed by the Clinical and Laboratory Standards Institute (CLSI) (EP-9)